Ethanol can increase the solubility of poorly soluble and hence present a higher drug concentration in the gastrointestinal tract. This may produce a faster and more effective absorption resulting in variable and/ or high drug plasma concentrations, both of which can lead to adverse drug reactions. In this work we therefore studied the solubility and absorption effects of nine diverse compounds when ethanol was present. The apparent solubility was measured using the lDiss Profiler Plus (pION, MA) in four media representing gastric conditions with and without ethanol. The solubility results were combined with in-house data on solubility in intestinal fluids (with and without ethanol) and pharmacokinetic parameters extracted from the literature and used as input in compartmental absorption simulations using the software GI-Sim. Apparent solubility increased more than 7-fold for non-ionized compounds in simulated gastric fluid containing 20% ethanol. Compounds with weak base functions (cinnarizine, dipyridamole and terfenadine) were completely ionized at the studied gastric pH and their solubility was therefore unaffected by ethanol. Compounds with low solubility in intestinal media and a pronounced solubility increase due to ethanol in the upper gastric compartments showed an increased absorption in the simulations. The rate of absorption of the acidic compounds indomethacin and indoprofen was slightly increased but the extent of absorption was unaffected as the complete doses were readily absorbed even without ethanol. This was likely due to a high apparent solubility in the intestinal compartment where the weak acids are ionized. The absorption of the studied non-ionizable compounds increased when ethanol was present in the gastric and intestinal media. These results indicate that concomitant intake of alcohol may significantly increase the solubility and hence, the plasma concentration for non-ionizable, lipophilic compounds with the potential of adverse drug reactions to occur.
Introduction
Poor hydration as a consequence of high lipophilicity is the main cause of the low aqueous solubility of modern drugs. In vivo, solubility in the gastrointestinal tract is mainly a result of the pHgradient and presence of naturally available lipids. The stomach has a low pH with a reported range of 1.7-3.3 (median of 2.5) and low concentrations of lipids. In contrast, in the small intestine, where most of the absorption occurs, the pH increases to 6.5-7.7 (median 6.9) with a bile salt and phospholipid concentration of 2.52 mM and 0.19 mM, respectively (Bergström et al., 2014) . The dissolution rate and apparent solubility (S app ) of ionizable drugs are dependent on their charge as a function of their dissociation constant (pKa) and the pH of the gastrointestinal milieu. This relationship is described with the Henderson-Hasselbalch equation (Hasselbalch, 1916) and results in bases carrying a positive charge in the stomach whereas acidic functions are neutral. When emptied into the small intestine, the bases become less charged whereas the acidic compounds typically become negatively charged. These changes in ionization make classical acidic drugs with a pKa < 5.5 significantly more soluble in the small intestine compared to the stomach. For weak bases with a pKa < 6, an increased solubility is achieved in the gastric compartment compared to the intestinal one and the compounds are at risk for precipitating when emptied from the stomach (Carlert et al., 2010; Psachoulias et al., 2011) . In early drug development platforms, surrogates for gastrointestinal fluids (e.g., fasted state simulated gastric and intestinal fluids, FaSSGF and FaSSIF, respectively) are used to mimic the dissolution in the gastrointestinal compartments (Galia et al., 1998; Vertzoni et al., 2005) .
Ethanol can act as a cosolvent and increase the S app in gastrointestinal fluids. This may therefore affect the absorption of poorly soluble drugs. Common modified release formulations carrying high doses of drugs have been shown to disintegrate prematurely and unload the complete dose in the small intestine in response to ethanol intake (Fadda et al., 2008; Walden et al., 2007) . This phenomenon is referred to as dose dumping and can lead to increased and potentially hazardous plasma concentrations and adverse side effects of drugs with narrow therapeutic window (Lennernäs, 2009) . A well-known example of this phenomenon is hydromorphone for which one formulation was withdrawn from the market in 2005 after reports of ethanol-induced, dose-dumping-related, adverse drug reactions (ADR). The withdrawn product was a capsule with an extended release formulation consisting of hotmelt extruded granules of the drug, ammonio methacrylate copolymer type b and ethylcellulose. The latter has been shown to be sensitive to ethanol in dissolution tests (Fadda et al., 2008) . Following this observation the FDA composed a number of substance specific guidelines (e.g., bupropion hydrochloride, morphine sulfate and trospium chloride) to test for ethanol sensitivity of modified release formulations. In these guidelines dissolution behavior should be assessed for 2 h with 0%, 5%, 20% and 40% v/v ethanol in an acidic medium reflecting the gastric milieu (Anand et al., 2011) .
We hypothesized that immediate release formulations of drugs with low solubility in gastrointestinal fluids may, in a similar fashion as extended release formulations during dose-dumping, show increased absorption in response to alcohol intake. This hypothesis is based on the large drug load of such compounds which is not dissolved during gastrointestinal transit under normal fasted conditions. If the presence of ethanol in gastrointestinal fluids increases the dissolution rate and/or the S app of a compound, it may also affect the absorption profile of that drug (Fig. 1) . Indeed, in a previous study investigating 22 compounds in FaSSIF, we found that nonionizable compounds and weak acids in particular were at a high risk for obtaining significantly different dissolution profiles when administered with ethanol. However, ethanol is rapidly absorbed in the intestinal tract and the impact on absorption was not revealed in the previous study. For instance, it has been shown that if ethanol is co-administered with water, the ethanol disappears from the gastric compartment within 30 min and half of the dose is emptied into the duodenum within 5 min (Levitt et al., 1997) . Other studies have shown that although the absorption of ethanol from the small intestine is fast, it is not instantaneous, and elevated levels of ethanol have been found in the upper small intestine up to 30 min after intake (Halsted et al., 1973) . It is clear that if ethanol is taken together with food it is diluted and the ethanol absorption is delayed. Human in vivo studies of drug ethanol sensitivity would require a combination of high drug doses with ethanol intake and are not ethically feasible. In this study we therefore employed in vitro solubility measurements and in silico absorption simulations to identify compounds potentially sensitive to concomitant ethanol intake.
Materials and methods

Data set
Nine model compounds were included in this study on the basis of their lipophilicity, aqueous solubility (with focus on poorly soluble compounds), and results from a previous study of ethanol sensitivity in FaSSIF (Fig. 2) (Fagerberg et al., 2012) . The data set included three acidic compounds (indomethacin, indoprofen and tolfenamic acid), three non-ionizable compounds (felodipine, griseofulvin and progesterone), and three weak bases (cinnarizine, dipyridamole and terfenadine); these compounds were selected to cover both charged and non-ionizable compounds with a diversity in physicochemical properties (Table 1) . Only compounds available in their free form were included to exclude effects from salt formation. ADMET Predictor (Simulations Plus, CA) was used to calculate lipophilicity expressed as log P and log D pH2.5 , and the total effective permeability (P eff ) for the nine compounds. Diffusivity in water was calculated according to the Stoke-Einstein's equation on the basis of the molecular volume estimated using ACD/ Chemsketch 12.0 (Advanced Chemical Development Inc, Canada). Pharmacokinetic parameters were gathered from the literature. All input data used in the computational simulations are summarized in Table 2 .
Dissolution media preparation
The composition of FaSSGF was a modification of the gastric medium described by Vertzoni et al. (2005) . No pepsin was included and the pH was increased from the suggested 1.6 to 2.5. The latter was done to reflect recent findings regarding the pH of human gastric-fluid aspirates (Kalantzi et al., 2006; Pedersen et al., 2013) and to avoid unnecessary wear on the stainless-steel fiber-optic dip probes used for concentration determination.
A NaCl solution with pH 2.5 (NaCl pH2.5 ) was prepared by dissolving 2 g NaCl in 0.9 L MilliQ water, after which the pH was adjusted to 2.5 by the addition of HCl before adjusting the final volume to 1 L. The resulting NaCl pH2.5 was sterile-filtered and stored at 8°C. NaCl pH2.5 with 20% ethanol (NaCl pH2.520%Ethanol ) was prepared in the same fashion except that 2.5 g NaCl was used and 20% (v/v) ethanol was added to the 1 L volume (final volume 1.2 L). The corresponding biorelevant dissolution media (BDM), i.e. FaSSGF and FaSSGF 20%Ethanol , were prepared by dissolving 6 mg SIF powder in 100 mL of each NaCl solutions.
Solubility determination
Apparent solubility was determined in the four different media using a three-channel lDiss Profiler Plus (pION, MA) described a Lipophilicity expressed as log P and log D pH2.5 . The number of rotatable bonds was calculated with Admet Predictor 6.5 (Simulations Plus, CA); molecular weight (MW), melting temperature (Tm) (O'Neil, 2001; Persson et al., 2013) , disassociation constant (pKa) of ionizable groups at 37°C (Fagerberg et al., 2012) . b a denotes acidic, n denotes neutral and b denotes basic function. a Diffusion coefficient and density were calculated based on molecular volume, as estimated by ACD/Chemsketch 12.0 (Advanced Chemical Development Inc., Canada) and/ or molecular weight. Human effective jejunal permeability (P eff ) was predicted with ADMET Predictor (Simulations Plus, CA). The plasma clearance (CL Plasma ) and volume of distribution (V d ) and compartmental parameters found in the Table A1 in Appendix A were taken from the literature (indomethacin (Obach et al., 2008) , indoprofen (Tamassia et al., 1976) , tolfenamic acid (Pedersen, 1994; Pentikäinen et al., 1981) , griseofulvin (Chiou and Riegelman, 1971) , felodipine (Sjögren et al., 2013) , progesterone ( previously (Fagerberg et al., 2010) . Each channel was calibrated with a standard curve before the dissolution assay. Estimated S app was used together with chromophore strength to select dip-probe path length. Compounds with high solubility and/or strong chromophores required the use of a short-path length while a longer one was used for compounds with weak chromophore and/or low S app . Before the experiments, an approximately twofold excess of drug powder compared to the estimated S app was weighed into the vials. Preheated media (15 mL, 37°C) were added to the vials at the start of the experiment and the temperature was held constant at 37 ± 0.5°C. The vials were sealed using parafilm to avoid evaporation and stirred at 100 rpm using magnetic stirrers. The experiment was terminated after a stable plateau representing the S app was reached but not before the 2 h period recommended by the FDA for ethanol sensitivity testing. Interference from solid particles of the excess powder in the vials was avoided by using the second derivative signal from collected absorbance spectra. The resulting dissolution profiles were analyzed with GraphPad Prism (GraphPad Software, CA) and a nonlinear, two-phase association equation was used to obtain the S app -value from the plateau. The results are presented as mean and standard deviations (n = 3). Lipid solubilization and the ethanol effect on S app at pH 2.5 were calculated as a fold increase (the ratio) of S app in FaSSGF or NaCl pH2.520%Ethanol over NaCl pH2.5 . Ethanol effects in FaSSGF were calculated as the ratio of S app in FaSSGF 20%Ethanol over FaSSGF. Standard errors (SE) for the mean fold-increase (FI) ratios were calculated according to
where A and B are mean S app in two media and rA and rB represent the corresponding standard deviation.
Absorption simulation
In silico simulations were performed with the absorption simulation software GI-Sim that has been thoroughly described elsewhere (Sjögren et al., 2013) . Briefly, GI-Sim deploys a compartmental physiological structure of the underlying intestinal physiology with nine gastrointestinal (GI) compartments coupled in series: the stomach (1), the small intestine (2-7) and the colon (8-9) Amidon, 1998, 1999; Yu et al., 1996) . To describe the plasma concentration-time profile, the GI model is linked to a pharmacokinetic model with up to three compartments. Physiological parameters for the GI compartments previously described were used, except that the gastric pH was somewhat elevated and set to 2.5 in analogy with in vitro solubility measurements (Sjögren et al., 2013) . In GI-Sim, undissolved particles and dissolved molecules flow from one GI compartment into the next. The particles may either dissolve or grow; dissolved material may partition into the bile salt micelles or is absorbed through the intestinal wall. Intestinal solubility, represented by previously reported S app in phosphate buffer pH 6.5 and FaSSIF (Fagerberg et al., 2012 (Fagerberg et al., , 2010 , was used as input for the concentration in the intestinal compartment. The pH-dependent solubility of an ionizable compound is traditionally calculated in GI-Sim according to the Henderson-Hasselbalch equation and the physiological pH in each GI compartment. However, since the gastric solubility was measured in this study, both gastric and intestinal in vitro values were used as input in the simulations.
In GI-Sim, dissolution rate is described by Fick's law together with the Nielsen stirring model (Nielsen, 1961) . Effective permeability describes the absorption and total membrane transport process that involves serial diffusion through an aqueous boundary layer adjacent to the intestinal wall and the intestinal membrane.
Absorption generally occurs in all GI compartments except the stomach. In this study we were interested in the effect on immediate release formulations of highly permeable compounds i.e., class 2 compounds in the biopharmaceutics classification system (BCS). These are poorly soluble and highly permeable and therefore the simulations only modeled absorption from the small intestinal compartments (compartments 2-7 in GI-Sim).
Specific solubility factors, obtained from the in vitro measurements, were implemented to account for the effect of ethanol on the solubility of the investigated compounds. FaSSGF 20%Ethanol and FaSSIF 20%Ethanol measurements were used for the stomach (GI compartment 1) and duodenum (GI compartment 2), respectively, in simulations of concomitant intake of ethanol. The simulations used the maximum oral doses prescribed. Two particle sizes were investigated to study their impact on the resulting dissolution. The first had a generic particle size with a diameter of 25 lm (d10 = 12.5 lm, d50 = 25 lm, d90 = 50 lm). A second particle size fraction with diameter of 5 lm (d10 = 2.5 lm, d50 = 5 lm, d90 = 10 lm) was studied to represent micronized powder. Default simulation time was set to 8 h. If the absorption was incomplete, the simulation was repeated with a longer simulation time, up to 24 h, to capture the entire absorption phase. In a second step, the simulations were repeated for compounds with a predicted 15% increase in AUC due to the ethanol effects. These further simulations were performed with ethanol only present in the stomach to investigate if an extraordinarily rapid absorption of ethanol from the duodenum still had the possibility to increase plasma drug concentration.
Results
Solubility in gastric media and ethanol effects
The low pH of the gastric media resulted in high S app values for cinnarizine, dipyridamole and terfenadine as a consequence of the complete ionization of these weak bases (Table 3) . Indomethacin, indoprofen and tolfenamic acid are weak acids with pKa values > 3.9 (Fagerberg et al., 2012) ; therefore at pH 2.5, they are predominantly neutral. This is reflected in the low S app in NaCl pH2.5 . The S app of the neutral compounds -felodipine, griseofulvin and progesterone -in the NaCl solution was also low, less than 15 lg/mL (Table 3) . Only two compounds, tolfenamic acid and felodipine, exhibited a higher S app in FaSSGF compared to NaCl pH2.5 (Fig. 3a) , indicating that the level of lipids present in FaSSGF was too low to significantly solubilize the studied compounds. All compounds present in their neutral form at pH 2.5 had higher solubility in NaCl pH2.5,20%Ethanol compared to that in blank medium (Fig. 3b) . The weak basic compounds were completely charged at pH 2.5 and were unaffected by lipid aggregates, ethanol content or combination thereof. The S app of felodipine and tolfenamic acid was over 20 times higher in medium with lecithin, taurocholate and ethanol than without (Fig. 3c) . The remaining non-ionizable compounds and weak acids showed 7-10-fold higher solubility in the ethanol-spiked FaSSGF compared to the NaCl solution. Similar trends were observed when FaSSGF with and without ethanol were compared. Here the weak bases were equally soluble in both media, whereas neutral compounds were up to 15-fold more soluble in ethanol containing FaSSGF (Fig. 4) .
Simulated absorption
Two of the model compounds with basic functions, cinnarizine and terfenadine, were unaffected by the simulated ethanol intake (Fig. 5) . However, the absorption of dipyridamole was increased considerably with a relative AUC increase greater than 40% and with a similar increase in peak plasma concentration (Table 4 ). The plasma peak concentration time (T max ) decreased almost 4.5 h. Indomethacin and indoprofen doses were according to the simulations readily absorbed in both the fasted state and with concomitant ethanol intake while approximately 80% of administered tolfenamic acid was absorbed. The predicted AUC of these acidic compounds was hence unaffected by concomitant ethanol intake. Indomethacin and indoprofen C max increased slightly while the C max of tolfenamic acid remained unchanged. For non-ionizable compounds the AUC increased between 15% (griseofulvin) and 105% (felodipine) when ethanol was present in the gastric and duodenal simulation compartments. The fraction absorbed of felodipine doubled; C max increased almost 150% and T max decreased by 1 h after simulated intake of alcohol. Progesterone AUC and C max increased with 17% and 16%, respectively, and T max decreased by 30 min as a result of the ethanol effect on S app .
The simulations with smaller particles (5 lm in diameter) led to a higher fraction of the dose absorbed and/or an overall more rapid absorption for all compounds. The changes in the plasma-concentration curves observed with ethanol were not as pronounced for the small particle size compared to the larger one (25 lm in diameter). Further, the simulations in which ethanol was excluded in the duodenal compartment showed substance-specific results. No effect on the absorption of dipyridamole, griseofulvin and progesterone was observed when ethanol only was present in the gastric compartment and hence, influenced the concentration reached in the stomach but not in the duodenum. However, the absorption of felodipine was still increased using this simulation protocol.
Discussion
The main characteristic of gastric fluids is their acidic pH which has a profound effect on the solubility of ionizable compounds. The FaSSGF used to mimic human gastric fluid contains 80 lM taurocholate and 20 lM lecithin, derived from soybean oil. Lecithin has a critical micelle concentration (CMC) well below 1 nM (King and Marsh, 1987) whereas taurocholate has a reported CMC of 6.3 mM (Yang et al., 2010) . The low concentration of taurocholate in FaSSGF in relation to its CMC implies that the bile salt may primarily have wetting effects during dissolution in the medium. A large fraction of the bile salt is likely to be dissolved in the bulk of the medium whereas the lecithin is likely found in liposomes together with the remainder of the taurocholate. The addition of ethanol to aqueous systems leads to a lower dielectric constant of the resulting mixture, which in turn leads to an increase in S app of nonpolar compounds. Indeed this was confirmed by our study since drugs that were non-ionized at the studied pH (2.5) generally had higher solubility in media containing 20% ethanol. The two most lipophilic compounds, tolfenamic acid and felodipine, were the compounds with the strongest positive effect on solubility by the presence of lipids and/or ethanol. Tolfenamic acid showed a slight increase in S app in media with ethanol. This was the only compound in the study that appeared to be effectively solubilized by the low concentrations of taurocholate and bile salt present in FaSSGF, with a close to 20 times higher S app in FaSSGF compared to that observed in the corresponding blank medium (NaCl pH2.5 ). This could potentially be a result of the high lipophilicity in combination with its relatively small size; tolfenamic acid had the lowest molecular weight (261.7) of the compounds. The larger substance, felodipine, was also solubilized by phospholipid aggregates in FaS-SGF but its S app was only doubled compared to that in NaCl pH2.5 . On the other hand, the effect of ethanol on felodipine S app was more pronounced. The addition of 20% ethanol to NaCl pH2.5 or FaSSGF led to a 25-fold and 15-fold increase, respectively. In comparison, the less lipophilic neutral compounds, griseofulvin and progesterone, were both unaffected by the lipids in FaSSGF. However, they exhibited an 8-10-fold increase in solubility after the inclusion of 20% ethanol to either NaCl pH2.5 or FaSSGF. The compounds with basic functions were highly charged and had considerably lower lipophilicity at pH 2.5 (log D pH2.5 ) compared to the other drugs. They all exhibited a relatively high S app due to being completely ionized and they were therefore unaffected by either lipid content or ethanol in the media. The observation that S app of uncharged and lipophilic compounds significantly increases in response to ethanol is in agreement with our previous results regarding ethanol effects in intestinal media (Fagerberg et al., 2012) .
The solubility classification in the BCS is based on dose number (Do) which is calculated according to
where M 0 is dose and V 0 is available volume (here set to 250 mL) (Oh et al., 1993) . A Do > 1 indicates that the complete dose cannot dissolve in 250 mL of medium while a Do < 1 indicates that the dose is soluble in this volume. None of the studied compounds obtained an increase in S app due to ethanol in FaSSGF that was high enough to cause a shift in Do when the highest prescribed dose was used for the calculation. Cinnarizine was completely soluble in both FaSSGF and FaSSGF 20%Ethanol while all other compounds were not. If this analysis were to be performed using a normal tablet strength rather than the highest prescribed dose, all weak bases in this study would have been soluble in all the media. A normal dose for felodipine (2.5 mg) gave rise to a Do shift from above 1 in FaSSGF to below 1 after addition of 20% ethanol. Compared to our previous study on ethanol effects on S app in intestinal media 20% ethanol in FaSSIF did induce a Do shift using the max doses of felodipine and indoprofen. These Do shifts in FaSSIF were the result of a moderate increase in S app due to 20% ethanol, with a 2-and 3-fold increase respectively for these compounds. Due to high dose and/or low initial S app in FaSSIF, no Do shift occurred as result of 20% ethanol for dipyridamole (19-fold increase), griseofulvin (8-fold), progesterone (7-fold) indomethacin and tolfenamic acid (3-fold). As the intestinal S app of terfenadine and cinnarizine did not increase with the addition of ethanol, neither was there any shift in Do for these compound in the simulated intestinal fluid (Fagerberg et al., 2012) . The computational simulations with GI-Sim revealed that although the solubility of indomethacin and indoprofen was increased with the addition of 20% ethanol in the gastric and duodenal compartments, the effects on absorption were small as the compounds were absorbed rapidly and completely in the fasted state. The small observed increase in C max is likely to be negligible. The decrease in T max could indicate a potential reduction in onset due to ethanol. This assumes however that no other parameters except the concentrations in the stomach and intestine affect the absorption and the resulting plasma concentration. The absorption of tolfenamic acid and the two basic compounds terfenadine and cinnarizine was also more or less unaffected by the simulated concomitant ethanol intake. For the latter two the absorption was reduced slightly due to a lower S app in duodenal media (FaSSIF with 20% ethanol) as a result of suppressed ionization caused by the ethanol. Dipyridamole is completely charged at the gastric pH but only slightly so at the intestinal pH where its S app is effectively increased by the addition of ethanol. This results in a higher extent and rate of absorption predicted by the simulations. The impact of the duodenal ethanol was revealed when repeating the simulations without ethanol in this compartment during which the 'ethanol' curve was superimposed on top of the curve without ethanol.
For the non-ionizable compounds, different plasma concentration curves were obtained when ethanol was included as compared to the fasted state. The absorption of griseofulvin and progesterone was slightly increased with around 15% higher values for the F abs , C max , and AUC for both compounds. The moderate increase in absorption of griseofulvin is surprising because this compound has been shown to exhibit strong food effects (Ogunbona et al., 1985) . Furthermore it is only slightly solubilized by lipid aggregates (Persson et al., 2005) compared to the effect ethanol has on its S app in gastric and intestinal media (Fagerberg et al., 2012) . One explanation for this is that the mixed lipid aggregates are present much longer in the intestinal fluid compared to the transiently elevated levels of the rapidly absorbed ethanol. The increased absorption of both progesterone and griseofulvin is also absent when ethanol is only present in the gastric compartment. Felodipine however, which is strongly affected by ethanol in both gastric and intestinal simulated media, maintained the increased absorption when ethanol was only present in the gastric compartment. There are two possible explanations for this result. First, the drug is effectively solubilized by the mixed lipid aggregates found in FaSSIF that help maintain the high amount of dissolved substance during the gastrointestinal transit time. Second, the equilibrium between the substance in solution and that solubilized in aggregates is rapid, which helps to push permeation through the gut wall.
Ethanol has previously been shown to increase the absorption or at least plasma concentration of drugs taken concomitantly with it. In humans, the plasma concentration of diazepam almost doubles due to enhanced absorption in the presence of even a small amount of hard liquor (Hayes et al., 1977) . Although this is a soluble BCS class I compound, it is lipophilic and neutral in intestinal media and may thus potentially dissolve quicker and be absorbed faster in the presence of alcohol with a higher plasma concentration peak as a result. The effects of ethanol on the in vivo absorption of acetylsalicylic acid (a soluble weak acid with pKa of $3.5 and low permeability) are ambiguous and range from negative (Melander et al., 1995) to absent (Hollander et al., 1981) in humans and even positive (Kato et al., 2010) in mice. A very high dose were given to the mice (0.5 g/kg) making the cosolvent effect of ethanol on acetylsalicylic acid solubility (Roberts et al., 2007) a possible reason for the enhanced absorption. The now withdrawn drug propoxyphene also obtained increased bioavailability when administered with ethanol in both humans (Girre et al., 1991) and dogs (Olsen et al., 1986) ; in both studies the authors attributed the increase to altered metabolism as a result of the ethanol intake. Ethanol first pass metabolism occurs in the gut wall primarily by alcohol dehydrogenases, and in the liver also through CYP2E1 (Lieber and Abittan, 1999) . The latter has been shown to metabolize other drugs such as theophylline and acetaminophen, and is inhibited by disulfiram. The findings obtained in this study support that the increased levels of propoxyphene most likely is an effect of a Simulation time is given in hours; increased time for griseofulvin, progesterone, cinnarizine and dipyridamole was used to allow maximal possible absorption for all compounds. Area under the plasma concentration curve (AUC) is calculated from t = 0 to t = simulation time. Maximum plasma concentration (C max ) represents the height of the plasma concentration peak. Plasma maximum time (T max ) indicates the plasma concentration peak time after simulation start. The fraction absorbed (F abs ) is the ratio between amount dose administered and absorbed substance.
interactions at the metabolic level. Propoxyphene is a weak base with a pKa of $9.5 and hence, will be completely ionized in both the gastric and intestinal compartment. Experimental results of other such model compounds studied herein and previously (Fagerberg et al., 2010) predict that ethanol will not increase the solubility of propoxyphene and this factor will therefore not affect the absorption. Another physiological factor affected by ethanol intake is the gastric emptying rate. Ethanol delays gastric emptying rate compared to intake of e.g. water, but the extent to which seems to be dependent on several different factors and e.g. gender (Horikoshi et al., 2013) , alcohol concentration and type of alcohol containing beverage (Franke et al., 2004 ) that is ingested have been suggested to affect emptying rate. The complex interplay between alcohol containing beverages and gastric emptying rate made us decide to use the fasted state gastric emptying rate defined in the GISim during simulations. A delayed transport of drug from the gastric compartment would likely reduce the absorption rate and increase T max . On the other hand, the delay could lead to more of the dose reaching the absorptive compartments of the small intestine in solution rather than as solid particles. If so, all compounds with high solubility in gastric media (whether because of ionization or increased solubility with ethanol) should show increased absorption. Indeed a large number of pharmacokinetic and pharmacodynamic interactions between ethanol and drugs have been reported in the literature see e.g. (Fraser, 1997; Weathermon and Crabb, 1999) . However, the focus of this study was to reveal the effect that changes in solubility have on the resulting absorption and for this reason, only this parameter was allowed to influence the simulations.
The compounds selected for this study were selected as model compounds on the basis of their diverse physicochemical properties and not that increased absorption rate would potentially lead to serious ADRs. A significant S app increase due to the presence of ethanol in the intestinal fluid does not necessarily imply that ADRs will occur if the drugs are taken together with liquor. Instead it should be viewed as one risk indicator among many. If the extent or rate of absorption of a drug due to ethanol intake is paired with a narrow therapeutic window, metabolic interactions, and/or with synergistic pharmacodynamics effects such as respiratory depression, then the increased gastrointestinal concentration obtained during concomitant ethanol intake may lead to potentially dangerous adverse side effects.
Conclusion
In this study we explored the potential effects of concomitant intake of ethanol on drug absorption. We focused on the effect on solubility and measured the gastric concentration reached at elevated ethanol levels. The data were analyzed together with previous data from simulated intestinal fluids using the computational simulation tool GI-Sim. It was found that non-ionized and lipophilic compounds were likely to have higher solubility in gastrointestinal fluids when ethanol was present and for these, concomitant intake of ethanol increased the absorption. If such compounds also have narrow therapeutic windows, the concomitant ethanol intake results in a higher risk of ADRs.
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